NCT02189720 2025-03-26
EAP-001
Catalyst Pharmaceuticals, Inc.
Approved for marketing
Clinical Trials
8 trialsNCT00872950 2022-04-11
LEMS
Lahey Clinic
Approved for marketing
NCT01825395 2021-10-06
3 4-DAP
University of Colorado, Denver
Approved for marketing
NCT02012933 2019-12-11
3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)
Oregon Health and Science University
No longer available
NCT00704925 2019-10-30
Treatment of Lambert-Eaton Syndrome With 3,4 DAP
University of California, Davis
No longer available
NCT00994916 2019-07-09
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
University of Pittsburgh
No longer available
NCT01373333 2016-07-20
34-DAP
The Cleveland Clinic
No longer available
NCT01378546 2013-07-18
Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP
Columbia University
No longer available